OncoMatch/Clinical Trials/NCT06305832
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Is NCT06305832 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Rezvilutamide and Androgen deprivation therapy (ADT) for prostate cancer.
Treatment: Rezvilutamide · Androgen deprivation therapy (ADT) — To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage PN0, PNX, PT3 (pathological)
Postoperative pathological stage pN0 or pNx; Postoperative pathological stage PT3/T4
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: endocrine therapy (goserrelin, levoprorelin, digarek, bicalutamide, abiraterone acetate, darotamine, apatamide, enzalutamide)
Previously received endocrine therapy for prostate cancer (including but not limited to goserrelin, levoprorelin, digarek, bicalutamide, abiraterone acetate, darotamine, apatamide, enzalutamide, etc.)
Cannot have received: pelvic radiotherapy
Previously received...pelvic radiotherapy
Lab requirements
Blood counts
Neutrophil count (ANC)≥1.5×10^9/L (no granulocyte colony-stimulating factor for 2 weeks prior to cycle 1, day 1); Platelet count (PLT)≥100×10^9/L (no transfusion within 2 weeks prior to day 1 of cycle 1); Hemoglobin (Hb) ≥90g/L
Kidney function
Serum creatinine (Cr)≤1.5×ULN or creatinine clearance > 50ml/min
Liver function
Total bilirubin (BIL)≤1.5×ULN; AST/SGOT or ALT/SGPT level ≤2.5×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50%
Adequate hematological and organ function tests within 4 weeks prior to the first study treatment, as defined below: Neutrophil count (ANC)≥1.5×10^9/L (no granulocyte colony-stimulating factor for 2 weeks prior to cycle 1, day 1); Platelet count (PLT)≥100×10^9/L (no transfusion within 2 weeks prior to day 1 of cycle 1); Hemoglobin (Hb) ≥90g/L; Serum creatinine (Cr)≤1.5×ULN or creatinine clearance > 50ml/min; Total bilirubin (BIL)≤1.5×ULN; Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) level ≤2.5×ULN; International Standardized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5×ULN; Left ventricular ejection fraction (LVEF) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06305832 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage PN0 or PNX or PT3 is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages